JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
ABSTRACT Introduction Janus kinase inhibitors (JAKi) have dramatically improved the
treatment of various autoimmune and myeloproliferative disorders. Recently, concern has …
treatment of various autoimmune and myeloproliferative disorders. Recently, concern has …
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
V Solitano, P Facheris, M Petersen, F d'Amico… - Autoimmunity …, 2024 - Elsevier
Abstract Background and Aims The Pharmacovigilance Risk Assessment Committee
(PRAC) proposed measures to address severe side effects linked to Janus kinase inhibitors …
(PRAC) proposed measures to address severe side effects linked to Janus kinase inhibitors …
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial
AW Armstrong, M Gooderham, C Lynde… - JAMA …, 2024 - jamanetwork.com
Importance New, effective, and well-tolerated oral therapies are needed for treating
psoriasis. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a …
psoriasis. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a …
JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review
F Atschekzei, S Traidl, J Carlens, K Schütz… - Frontiers in …, 2024 - frontiersin.org
Objective The signal transducer and activator of transcription 3 (STAT3) gain-of-function
(GOF) syndrome (STAT3-GOF) is an inborn error of immunity (IEI) characterized by diverse …
(GOF) syndrome (STAT3-GOF) is an inborn error of immunity (IEI) characterized by diverse …
Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary
PC Taylor, A Balsa, AB Mongey, M Filková… - Rheumatology and …, 2024 - Springer
This commentary explores the potential cardiovascular (CV) benefits of combining
methotrexate (MTX) and Janus kinase inhibitors (JAKis) in the treatment of rheumatoid …
methotrexate (MTX) and Janus kinase inhibitors (JAKis) in the treatment of rheumatoid …
Changes in characteristics of patients initiating and discontinuing advanced therapies for rheumatoid arthritis following the release of safety data
S Song, BR England, B Sauer, MD George… - Arthritis care & …, 2024 - Wiley Online Library
Objective The objective of this study was to determine the impact of emerging safety data on
practice patterns by describing the characteristics of patients initiating and discontinuing …
practice patterns by describing the characteristics of patients initiating and discontinuing …
A systematic overview of contraindications and special warnings for biologic and targeted synthetic disease modifying antirheumatic drugs: establishing a framework …
L Skaarup, E Ingrid, A Sepriano, E Nikiphorou… - Drug Safety, 2024 - Springer
Abstract Background/Aim The purpose of this review is to provide an overview of the
contraindications, special warnings, and boxed warnings with the aim to establish a …
contraindications, special warnings, and boxed warnings with the aim to establish a …
Comparative effectiveness of upadacitinib and tofacitinib in ulcerative colitis: a US propensity-matched cohort study
Methods: We conducted a retrospective cohort study using TriNetX, a multi-institutional
database, to compare the effectiveness of upadacitinib and tofacitinib in patients with UC …
database, to compare the effectiveness of upadacitinib and tofacitinib in patients with UC …
[HTML][HTML] Survey of Potential Drug Interactions, Use of Non-Medical Health Products, and Immunization Status among Patients Receiving Targeted Therapies
R Rajj, N Schaadt, K Bezsila, O Balázs, MB Jancsó… - Pharmaceuticals, 2024 - mdpi.com
In recent years, several changes have occurred in the management of chronic
immunological conditions with the emerging use of targeted therapies. This two-phase cross …
immunological conditions with the emerging use of targeted therapies. This two-phase cross …
An evaluation of mirikizumab for the treatment of ulcerative colitis
C White, PM Irving - Expert Opinion on Biological Therapy, 2024 - Taylor & Francis
Introduction Treatment of ulcerative colitis (UC) aims to reduce symptoms and complications
by decreasing intestinal inflammation. A proportion of patients do not respond to, do not …
by decreasing intestinal inflammation. A proportion of patients do not respond to, do not …